Encompass Health (EHC) 8-K Regulation FD Disclosure

Volume:

•Expect 1.0% to 2.0% discharge growth in Q4 2011

−Strong volume comparison in Q4 2010 of 5.9%

•Would bring full-year discharge growth to between 4.9% and 5.2%

Guidance confirmation for full year 2011:

    •Full-year Adjusted EBITDA (1) guidance of $450 million to $455 million

    •Full-year earnings per share guidance of $1.18 to $1.23 per basic share

Adjusted Free Cash Flow (1) :

    •Expect full-year adjusted free cash flowto be at least $210 million

Q4 2011 Observations (as of December 14, 2011)

1

(1) Reconciliation to GAAP provided on slides 49, 88, and 89 of the Q3 2011 Investor Reference Book

Exhibit 99.1